|
Real-world treatment patterns and outcomes in US patients (pts) with advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy (PBC) and anti–PD-(L)1 treatment. |
| |
|
Honoraria - Galvanize Therapeutics |
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Novocure; Picture Health; Regeneron; Taiho Oncology; Takeda |
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst) |
| |
|
Employment - GlaxoSmithKline |
| |
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
| |
|
Employment - GlaxoSmithKline |
| |
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
| |
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
| |
|
No Relationships to Disclose |
| |
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
Consulting or Advisory Role - OPEN Health |